Now ketamine, a glutamatergic NMDA receptor antagonist, may provide a mechanism that could link these pathways. Figure 1: A schematic of how ketamine may lead to an overall excitation in the cortex.

7 426–437; 2008). Increased levels of glutamate have been found in the frontal cortex of patients with MDD, and the non-selective NMDA receptor antagonist ketamine has shown antidepressant ...

Thus, finding more effective treatments is a primary aim of medical researchers. Ketamine, an NMDA receptor antagonist, commonly used as an anesthetic, has attracted the attention of many researchers ...

This information is critical to understanding not only how best to use ketamine, but also to developing similar drugs. Ketamine binds to a class of neurotransmitter receptors called ...

This information is critical to understanding not only how best to use ketamine, but also to developing similar drugs. Selective effects on NMDA receptors Ketamine binds to a class of neurotransmitter ...

Ketamine affects several receptors and pathways in the brain and body, with one key pathway involving glutamate. As an NMDA receptor antagonist, ketamine blocks glutamate from binding to NMDA ...

The pharmacological action of ketamine mainly involves NMDA receptor antagonism and is similar to chemical compounds such as ...